Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2011, Article ID 434375, 5 pages
http://dx.doi.org/10.1155/2011/434375
Clinical Study

Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early Mortality

1Department of Internal Medicine and Infectious Diseases, University Medical Centre Utrecht, F02.126, Postbus 85500, 3508 GA Utrecht, The Netherlands
2Ndlovu Medical Centre, Elandsdoorn, P.O. Box 1508, Groblersdal 0470, South Africa

Received 10 June 2010; Accepted 18 October 2010

Academic Editor: Esper Kallas

Copyright © 2011 Roos E. Barth et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Rosen, M. P. Fox, and C. J. Gill, “Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review,” PLoS Medicine, vol. 4, no. 10, article e298, pp. 1691–1701, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. R. E. Barth, M. F. S. van der Loeff, R. Schuurman, A. I. Hoepelman, and A. M. Wensing, “Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review,” The Lancet Infectious Diseases, vol. 10, no. 3, pp. 155–166, 2010. View at Publisher · View at Google Scholar
  3. G. P. Bisson, R. Gross, J. B. Strom et al., “Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy,” AIDS, vol. 20, no. 12, pp. 1613–1619, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Kantor, L. Diero, A. Delong et al., “Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings,” Clinical Infectious Diseases, vol. 49, no. 3, pp. 454–462, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. J. G. van Oosterhout, L. Brown, R. Weigel et al., “Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria,” Tropical Medicine and International Health, vol. 14, no. 8, pp. 856–861, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Keiser, “Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring,” AIDS, vol. 23, no. 14, pp. 1867–1874, 2009. View at Publisher · View at Google Scholar
  7. R. E. Barth, J. T. M. van der Meer, A. I. M. Hoepelman et al., “Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 27, no. 10, pp. 977–984, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. WHO, “Antiretroviral therapy for HIV infection in adults and adolescents,” Recommendations for a public health approach, 2006, http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf.
  9. A. Boulle, P. Bock, M. Osler et al., “Antiretroviral therapy and early mortality in South Africa,” Bulletin of the World Health Organization, vol. 86, no. 9, pp. 678–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Collazos, V. Asensi, and J. A. Cartón, “Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART,” AIDS, vol. 21, no. 7, pp. 835–843, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. C. Chen, J. K.-L. Yu, A. D. Harries et al., “Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi,” Tropical Medicine and International Health, vol. 13, no. 4, pp. 513–519, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Seyler, X. Anglaret, N. Dakoury-Dogbo et al., “Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire,” Antiviral Therapy, vol. 8, no. 5, pp. 385–393, 2003. View at Google Scholar · View at Scopus
  13. E. Nicastri, S. Leone, C. Angeletti et al., “Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review,” Journal of Antimicrobial Chemotherapy, vol. 60, no. 4, pp. 724–732, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Kumarasamy, V. Madhavan, K. K. Venkatesh et al., “High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings,” Clinical Infectious Diseases, vol. 49, no. 2, pp. 306–309, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Soria, K. Porten, J.-C. Fampou-Toundji et al., “Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-1infected patients,” Antiviral Therapy, vol. 14, no. 3, pp. 339–347, 2009. View at Google Scholar · View at Scopus
  16. A. Cozzi-Lepri, A. N. Phillips, J. Martinez-Picado et al., “Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings,” Journal of Infectious Diseases, vol. 200, no. 5, pp. 687–697, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. J. A. Bartlett and J. F. Shao, “Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries,” The Lancet Infectious Diseases, vol. 9, no. 10, pp. 637–649, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Laurent, N. F. N. Gueye, C. T. Ndour et al., “Long-term benefits of highly active antiretroviral therapy in senegalese HIV-1-infected adults,” Journal of Acquired Immune Deficiency Syndromes, vol. 38, no. 1, pp. 14–17, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Kouanfack, C. Montavon, C. Laurent et al., “Low levels of antiretroviral-resistant HIV infection in a routine clinic in cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment,” Clinical Infectious Diseases, vol. 48, no. 9, pp. 1318–1322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. S. Walker, “Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa,” AIDS, vol. 20, no. 10, pp. 1391–1399, 2006. View at Publisher · View at Google Scholar